FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
227 letters match. Newest first.
-
DrugsABR Laboratory LLC
FDA warned ABR Laboratory, a contract drug testing lab, that unverified microbial test methods and missed investigations made tested drugs adulterated.
High risk -
DrugsStrukmyer LLC dba Strukmyer Medical
Strukmyer Medical was cited for current good manufacturing practice violations after FDA found repeated microbial contamination in water used to make OTC drugs.
High risk -
DrugsShantou Kangjie Daily Chemical Industry Co., Ltd
FDA warns Shantou Kangjie over CGMP failures for OTC drugs, including untested ethanol and no quality unit.
High risk -
DrugsAtlanta Supersource, Inc.
Atlanta Supersource made OTC hand sanitizers on equipment shared with toxic industrial chemicals and lacked testing, FDA says.
High risk -
DrugsAkron Formulations India Private Limited
Akron Formulations India's over-the-counter drugs are adulterated due to manufacturing quality (CGMP) failures, including unqualified active ingredient (API) suppliers and inadequate microbial testing.
High risk -
DrugsGuangzhou Four E’s Scientific Co., Ltd.
FDA warns Guangzhou Four E’s over CGMP failures for OTC drugs, including a sterile-labeled product with inadequate sterility assurance.
High risk -
DrugsCatwalk Cosmetic Laboratories Pty Ltd.
FDA warns South African over-the-counter drug maker Catwalk Cosmetic Laboratories of current good manufacturing practice violations and import alert.
High risk -
DrugsHangzhou Huiji Biotechnology Co., Ltd.
FDA warned Hangzhou Huiji Biotechnology over CGMP failures in OTC hand sanitizers, including missing glycerin and ethanol safety tests.
High risk -
DrugsOriginitalia SRL
FDA warns Originitalia SRL over manufacturing quality failures in OTC drugs, including untested active ingredient and missing release testing.
High risk -
DrugsMultaler et Cie SAS
FDA cites Multaler et Cie for manufacturing failures and unapproved sunscreen after April 2024 inspection.
High risk -
DrugsSoliteint Kozmetikai KFT
Hungarian contract maker Soliteint Kozmetikai failed to test OTC pain-relief drugs and ingredients, FDA says; U.S. production halted.
High risk -
DrugsOmni Lens Pvt. Ltd.
FDA warns Omni Lens about CGMP failures and misbranding of ophthalmic OTC drugs made by unregistered contract manufacturers.
High risk -
DrugsOutin Futures Corp.
FDA warned Outin Futures, a Korean drug manufacturer, of CGMP violations and sunscreen misbranding after a March 2024 inspection.
High risk -
DrugsMakra Kozmetika D.O.O.
FDA warns Makra Kozmetika over OTC drug manufacturing violations, including missing batch and ingredient testing, after April 2024 inspection.
High risk -
DrugsClean Solutions LLC
FDA warned Clean Solutions LLC that its OTC hand soaps and sanitizer were adulterated because it released drugs without component or finished-product testing.
High risk -
DrugsAvaria Health & Beauty Corp.
FDA warns Canadian maker Avaria Health & Beauty over CGMP failures in OTC drug products, including skipped ingredient identity testing.
High risk -
DrugsOrean Personal Care Ltd.
FDA warned Orean Personal Care Ltd. that repeat manufacturing failures make its OTC drugs adulterated.
High risk -
DrugsMedia Networks Sydney Pty Limited
Media Networks Sydney failed to properly list Mylanta 2go Antacid and Microlax Enema with FDA, making them misbranded.
Low -
DrugsLS Promotions Inc.
LS Promotions Inc. failed to adequately test and validate its OTC sunscreens, lip balm and hand sanitizer, making them adulterated drugs.
High risk -
DrugsNowrez & Ismail Shukri Company
FDA warns Jordanian OTC drug maker Nowrez & Ismail Shukri over CGMP violations and import alert.
High risk -
DrugsYahon Enterprise Co., Ltd.
FDA warned Yahon Enterprise over manufacturing quality failures for OTC antiseptic wipes after a December 2023 inspection.
High risk -
DrugsYangZhou SuXiang Medical Instrument Co., Ltd.
FDA warns YangZhou SuXiang Medical Instrument over manufacturing quality failures and import alert for OTC drugs.
High risk -
DrugsMax Chemical Inc.
FDA warned Max Chemical Inc. in San Juan, Puerto Rico, that its OTC drug manufacturing violated CGMP, making its drugs adulterated.
High risk -
DrugsArt of Beauty Company, Inc.
FDA warned Art of Beauty over manufacturing-rule violations in OTC hand sanitizer, including missing component and finished-product testing.
High risk -
DrugsreBom Co., Ltd.
reBom failed current good manufacturing practice for OTC drugs, including inadequate stability and component testing.
High risk -
DrugsFancystage Unipessoal, LDA
FDA warned Portugal OTC drug maker Fancystage Unipessoal of repeated CGMP failures, untested ingredients, unvalidated processes and misbranded fluoride mouthwash.
High risk -
DrugsCosmetic Solutions, LLC
FDA warns Cosmetic Solutions over manufacturing failures and unapproved OTC drugs at Boca Raton plant.
High risk -
DrugsAruba Aloe Balm N.V.
Aruba Aloe Balm N.V. made OTC drugs with methanol-contaminated ethanol and failed CGMP, prompting recall and import alert.
High risk -
DrugsNatuzen Co., Ltd.
Natuzen Co., Ltd. failed drug manufacturing rules for OTC products including Atoren Hand Sanitizer, with no methanol testing, cleaning validation, or quality unit.
High risk -
DrugsWestwood Laboratories LLC
FDA warned Westwood Laboratories after an inspection found inadequate investigations, raw material testing, lab controls, and water/cleaning controls for OTC drugs.
High risk -
DrugsCohere Beauty
FDA cites Cohere Beauty for unvalidated OTC drug manufacturing and inadequate quality oversight at its Santa Fe Springs facility.
Medium -
DrugsGlobal Cosmetics Company Limited
FDA warns Global Cosmetics over manufacturing quality failures in OTC hand sanitizer, including no methanol testing of ethanol.
High risk -
DrugsC&T Dream Co., Ltd.
C&T Dream failed CGMP (current good manufacturing practice) for its over-the-counter Dry Skin Healing Ointment, including identity testing and process validation.
High risk -
DrugsMaster Paints & Chemicals Corp.
FDA warned Master Paints & Chemicals Corp. over inadequate testing and quality oversight for OTC drugs including hand sanitizer.
High risk -
DrugsJiangsu Meifan Biotechnology Co. Ltd.
FDA cites Jiangsu Meifan Biotechnology for OTC drug manufacturing-rule failures and import alert.
High risk -
DrugsBodywell Natural Skin Care Inc.
FDA warned Bodywell Natural Skin Care that its OTC hand sanitizer and Dermalere creams were adulterated due to CGMP failures and unapproved drug claims.
High risk -
DrugsHigley Industries, Inc.
FDA warns Higley Industries over CGMP failures in OTC drug manufacturing, including untested ethanol and glycerin.
High risk -
DrugsCosmetic Specialty Labs, Inc.
FDA warned Cosmetic Specialty Labs after an inspection found manufacturing failures in OTC drugs and an unlisted product.
High risk -
DrugsThai Nakorn Patana Co., Ltd.
FDA warns Thai Nakorn Patana over manufacturing quality violations, including missing identity and strength testing before release of OTC drugs.
High risk -
DrugsDelsam Pharma LLC
Delsam Pharma distributed non-sterile, contaminated artificial tears and eye ointment made by its contract manufacturer, FDA found.
High risk -
DrugsNingbo Poplar Daily-Use
FDA warned Ningbo Poplar Daily-Use that its OTC drugs had manufacturing quality failures in testing, component identity checks, and stability data.
High risk -
DrugsNantong Furuida Packaging Products Co., Ltd.
Nantong Furuida, an over-the-counter drug manufacturer, failed required manufacturing controls and methanol checks, leading to an FDA import alert.
High risk -
DrugsWoorilife & Health
Woorilife & Health, a South Korean OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.
High risk -
DrugsInopak, Ltd.
Inopak, Ltd. was warned of CGMP (current good manufacturing practice) violations after inspection: poor quality oversight of contract-made hand sanitizer and missing stability testing.
High risk -
DrugsWipro Unza Singapore Private, Limited
FDA cites Wipro Unza Singapore for refusing OTC hand sanitizer records, leading to import alert.
High risk -
DrugsPatcos Cosmetics Pvt. Ltd.
Patcos Cosmetics, an Indian OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.
High risk -
DrugsDextrum Laboratories Inc.
FDA found Dextrum Laboratories, an over-the-counter drug contract manufacturer, failed identity testing, toxic glycol checks, water monitoring, and process validation.
High risk -
DrugsAmLion Toothpaste Mfg. Sdn. Bhd.
FDA cites AmLion Toothpaste in Malaysia for CGMP failures, including no testing of glycerin and sorbitol for DEG/EG; firm stays on import alert.
High risk -
DrugsCerci Kozmetik Ve Otel Ekipmanlari Pazarlama Ic Ve Dis Ticaret Limited Sirketi
FDA: Turkish OTC drug maker Cerci shipped to the U.S. without finished-product identity and strength testing.
High risk -
DrugsXiamen Wally Bath Manufacture Co., Ltd.
FDA warns Xiamen Wally Bath over current good manufacturing practice failures for over-the-counter hand sanitizer, including raw material and release testing gaps.
High risk